Mechanistic description
As a translational thesis, the debate supports prioritizing upstream correction of glial lipid handling over blunt direct SREBP2 suppression. This is strategically attractive because it could normalize ER sterol sensing, apoE particle quality, and neuronal support simultaneously, but it remains contingent on first proving that ABCA1 and/or lysosome-to-ER rescue actually corrects SCAP-SREBP2 retention.
Evidence for (3)
LXR-ABCA1 pathway activation improves glial lipid phenotypes and apoE biology in APOE4-relevant systems.
ApoE4/tau preclinical work supports benefit from improving upstream lipidation programs.
The mechanistic literature suggests ER-sensing defects would be better normalized by fixing trafficking than by suppressing a downstream transcription factor.
Evidence against (3)
No head-to-head study yet shows upstream rescue is superior to selective SREBP2 modulation for neuronal protection.
Benefits of LXR agonism may arise from broad anti-inflammatory or lipid-droplet effects rather than specific SCAP-INSIG restoration.
LXR agonists have substantial peripheral lipid liabilities, while direct SREBP2 modulation remains mechanistically unproven but not excluded.
Bayesian persona consensus
scidex.consensus.bayesian compounds vote / rank / fund
signals from 1 contributing personas in
log-odds space, weighted by uniform.
Prior 50%.